VivoSeq
Immunology

Scleroderma

48

Pipeline Programs↗

8

Active Trials↗

23

Companies Involved↗

Scleroderma is a moderately active landscape with 48 programs across 23 companies. The most active players are Teva, Amphastar Pharmaceuticals, Inc., United Therapeutics. 6 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

11/100

Mech. Concentration

11/100

Completion Rate

84/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 1A

Amphastar Pharmaceuticals, Inc.

1 program

Phase 1United Therapeutics logo

United Therapeutics

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2G

Genzyme, a Sanofi Company

1 program

Phase 2A

Alaunos Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Mycophenolate Mofetil

Roche

Ambrisentan

Gilead

Hyperpolarized Xe129

University of Kansas Medical Center

MMF Immunosuppression

Wondercel Biotech (ShenZhen)

Clopidogrel Treatment

University Hospital, Bordeaux

Phase 19

Divalproex Sodium

Teva

Anifrolumab

AstraZeneca

Fludarabine

Sanofi

Thymoglobulin

Sanofi

Botulinum Toxin

Meshalkin Research Institute of Pathology of Circulation

Phase 217

Riociguat

Bayer

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Cyclophosphamide

Baxter Healthcare Corporation

Filgrastim

Eastern Cooperative Oncology Group

Anti-Thymocyte Globulin

Novartis

Phase 311

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Sildenafil

Viatris Specialty LLC

Tadalafil

Eli Lilly

Domperidone

Johnson & Johnson

Nintedanib

Boehringer Ingelheim

Approved6

Belumosudil

Kadmon, a Sanofi Company

Lidocaine

MEDRx USA, Inc.

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Influenza Vaccine

Novartis

Acetylsalicylic Acid

Bayer

Analysis

Modality Breakdown

86%

Small molecule

49 of 57 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody35%Protein / enzyme35%Cell therapy12%Vaccine12%

Small molecule leads; the ring shows all 57 classified programs, each share of the total. Modality classified for 98% of 59 pipeline programs.

Analysis

Trial Status

50

clinical trials

Completed32 · 64%
Recruiting5 · 10%
Unknown status4 · 8%
Terminated4 · 8%
Active, not recruiting3 · 6%
Withdrawn2 · 4%

Clinical Trials

Trial Activity

50 trials

Platform Clinical Study for Conquering Scleroderma
Recruiting·SScleroderma Research Foundation, Inc.·Phase 2·NCT06195072·400 enrolled
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
Recruiting·UUniversity of Patras·N/A·NCT07491523·35 enrolled
Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma
Recruiting·KKhon Kaen University·Phase 3·NCT07245238·36 enrolled
Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.
Recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT04356755·32 enrolled
Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Recruiting·UUniversity Hospital, Bordeaux·Preclinical·NCT05098704·90 enrolled
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
Active, not recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT07080125·2,000 enrolled
MRI for Screening and Monitoring Scleroderma ILD
Active, not recruiting·UUniversity of Kansas Medical Center·N/A·NCT05204355·25 enrolled
Pilot Exploratory Parallel-Group Randomized Controlled Trial to Evaluate a Personalized Online Occupational Therapy Intervention Versus Usual Care in Adults With Scleroderma
Active, not recruiting·UUniversidad de Zaragoza·Preclinical·NCT07661836·24 enrolled
Riociguat in Scleroderma Associated Digital Ulcers
Completed·—·Phase 2·NCT02915835·17 enrolled
Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00077584·188 enrolled
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Completed·SSanjay Gandhi Postgraduate Institute of Medical Sciences·Phase 3·NCT00626665·25 enrolled
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Completed·JJohns Hopkins University·Phase 3·NCT02165111·40 enrolled
Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
Completed·UUniversity Hospital, Lille·Phase 3·NCT01295736·84 enrolled
Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients
Completed·FFederal University of São Paulo·Phase 4·NCT03558854·70 enrolled
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT00930683·34 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)